Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

(2010) Colin A Purdie et al.   HISTOPATHOLOGY

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

(2009) S M Tovey et al.   BRITISH JOURNAL OF CANCER

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

(2008) S. Ménard et al.   ANNALS OF ONCOLOGY

HER2-Positive Breast Cancer: Current Treatment Strategies

(2008) Edith A. Perez et al.   CANCER INVESTIGATION

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE